Therapeutic potential of histone deacetylase inhibitors in pancreatic cancer

Cancer Letters

Volumn 347, Issue 2, 2014, Pages 183-190

  Feng, Wan ^a   Zhang, Bin ^a   Cai, Dawei ^a   Zou, Xiaoping ^a  

^a MEDICAL SCHOOL OF NANJING UNIVERSITY   (China)

Author keywords

Combination therapy; HDAC inhibitors; Histone deacetylases; Pancreatic cancer

Indexed keywords

BORTEZOMIB; CAPECITABINE; DACINOSTAT; ENTINOSTAT; EPIRUBICIN; ETOPOSIDE; FLUOROURACIL; GEFITINIB; GEMCITABINE; HISTONE DEACETYLASE; HISTONE DEACETYLASE 1; HISTONE DEACETYLASE 2; HISTONE DEACETYLASE 3; HISTONE DEACETYLASE INHIBITOR; IRINOTECAN; MOCETINOSTAT; PANOBINOSTAT; PROTEASOME INHIBITOR; SALINOSPORAMIDE A; TACEDINALINE; VALPROIC ACID; VORINOSTAT;

ANEMIA; ANGIOGENESIS; ANOREXIA; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; CANCER SURVIVAL; CELL CYCLE ARREST; CELL CYCLE PROGRESSION; DIARRHEA; DRUG DOSE REDUCTION; DRUG SCREENING; DRUG STRUCTURE; DRUG TOLERABILITY; FATIGUE; GASTROINTESTINAL DISEASE; GASTROINTESTINAL TOXICITY; HEMATOLOGIC DISEASE; HUMAN; LEUKOPENIA; LYMPHOCYTOPENIA; METASTASIS INHIBITION; MICROARRAY ANALYSIS; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PANCREAS CANCER; PLEIOTROPY; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; SHORT SURVEY; SIDE EFFECT; THROMBOCYTOPENIA; TUMOR GROWTH; UPREGULATION; VOMITING;

COMBINATION THERAPY; HDAC INHIBITORS; HISTONE DEACETYLASES; PANCREATIC CANCER;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; HISTONE DEACETYLASE INHIBITORS; HUMANS; PANCREATIC NEOPLASMS;

EID: 84898406503     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2014.02.012     Document Type: Review

References (110)

1. Vincent A., Herman J., Schulick R., Hruban R.H., Goggins M. Pancreatic cancer. Lancet 2011, 378:607-620.
2. Siegel R., Naishadham D., Jemal A. Cancer statistics, 2012. CA Cancer J. Clin. 2012, 62:10-29.
3. Burris H.R., Moore M.J., Andersen J., Green M.R., Rothenberg M.L., Modiano M.R., Cripps M.C., Portenoy R.K., Storniolo A.M., Tarassoff P. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J. Clin. Oncol. 1997, 15:2403-2413.
4. Rivera F., López-Tarruella S., Vega-Villegas M.E., Salcedo M. Treatment of advanced pancreatic cancer: from gemcitabine single agent to combinations and targeted therapy. Cancer Treat. Rev. 2009, 35:335-339.
5. Moore M.J., Goldstein D., Hamm J., Figer A., Hecht J.R., Gallinger S., Au H.J., Murawa P., Walde D., Wolff R.A. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J. Clin. Oncol. 2007, 25:1960-1966.
6. Troiani T., Martinelli E., Capasso A., Morgillo F., Orditura M., De Vita F., Ciardiello F. Targeting EGFR in pancreatic cancer treatment. Curr. Drug Targets 2012, 13:802-810.
7. Schneider G., Hamacher R., Eser S., Friess H., Schmid R.M., Saur D. Molecular biology of pancreatic cancer-new aspects and targets. Anticancer Res. 2008, 28:1541-1550.
8. Ito T., Kojima T., Yamaguchi H., Kyuno D., Kimura Y., Imamura M., Takasawa A., Murata M., Tanaka S., Hirata K. Transcriptional regulation of claudin-18 via specific protein kinase C signaling pathways and modification of DNA methylation in human pancreatic cancer cells. J. Cell. Biochem. 2011, 112:1761-1772.
9. Giovannetti E., Funel N., Peters G.J., Del Chiaro M., Erozenci L.A., Vasile E., Leon L.G., Pollina L.E., Groen A., Falcone A. MicroRNA-21 in pancreatic cancer: correlation with clinical outcome and pharmacologic aspects underlying its role in the modulation of gemcitabine activity. Cancer Res. 2010, 70:4528-4538.
10. Vincent A., Omura N., Hong S.-M., Jaffe A., Eshleman J., Goggins M. Genome-wide analysis of promoter methylation associated with gene expression profile in pancreatic adenocarcinoma. Clin. Cancer Res. 2011, 17:4341-4354.
11. Fukushige S., Horii A. Road to early detection of pancreatic cancer: attempts to utilize epigenetic biomarkers. Cancer Lett. 2012.
12. Li A., Omura N., Hong S.-M., Vincent A., Walter K., Griffith M., Borges M., Goggins M. Pancreatic cancers epigenetically silence SIP1 and hypomethylate and overexpress miR-200a/200b in association with elevated circulating miR-200a and miR-200b levels. Cancer Res. 2010, 70:5226-5237.
13. Lee K.-H., Lotterman C., Karikari C., Omura N., Feldmann G., Habbe N., Goggins M.G., Mendell J.T., Maitra A. Epigenetic silencing of MicroRNA miR-107 regulates cyclin-dependent kinase 6 expression in pancreatic cancer. Pancreatology 2009, 9:293-301.
14. Zhang S., Hao J., Xie F., Hu X., Liu C., Tong J., Zhou J., Wu J., Shao C. Downregulation of miR-132 by promoter methylation contributes to pancreatic cancer development. Carcinogenesis 2011, 32:1183-1189.
15. McCleary-Wheeler A.L., Lomberk G.A., Weiss F.U., Schneider G., Fabbri M., Poshusta T.L., Dusetti N.J., Baumgart S., Iovanna J.L., Ellenrieder V. Insights into the epigenetic mechanisms controlling pancreatic carcinogenesis. Cancer Lett. 2012.
16. Bernstein B.E., Meissner A., Lander E.S. The mammalian epigenome. Cell 2007, 128:669-681.
17. Venugopal B., Evans T. Developing histone deacetylase inhibitors as anti-cancer therapeutics. Curr. Med. Chem. 2011, 18:1658-1671.
18. Epping M.T., Bernards R. Molecular basis of the anti-cancer effects of histone deacetylase inhibitors. Int. J. Biochem. Cell Biol. 2009, 41:16-20.
19. Lane A.A., Chabner B.A. Histone deacetylase inhibitors in cancer therapy. J. Clin. Oncol. 2009, 27:5459-5468.
20. Minucci S., Pelicci P.G. Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer. Nat. Rev. Cancer 2006, 6:38-51.
21. Choudhary C., Kumar C., Gnad F., Nielsen M.L., Rehman M., Walther T.C., Olsen J.V., Mann M. Lysine acetylation targets protein complexes and co-regulates major cellular functions. Science 2009, 325:834-840.
22. Ellis L., Atadja P.W., Johnstone R.W. Epigenetics in cancer: targeting chromatin modifications. Mol. Cancer Ther. 2009, 8:1409-1420.
23. Spange S., Wagner T., Heinzel T., Krämer O.H. Acetylation of non-histone proteins modulates cellular signalling at multiple levels. Int. J. Biochem. Cell Biol. 2009, 41:185-198.
24. Marks P.A. Histone deacetylase inhibitors: a chemical genetics approach to understanding cellular functions. Biochim. Biophys. Acta (BBA) - Gene Regul. Mech. 2010, 1799:717-725.
25. Schrump D.S. Cytotoxicity mediated by histone deacetylase inhibitors in cancer cells: mechanisms and potential clinical implications. Clin. Cancer Res. 2009, 15:3947-3957.
26. Lehmann A., Denkert C., Budczies J., Buckendahl A.-C., Darb-Esfahani S., Noske A., Müller B., Bahra M., Neuhaus P., Dietel M. High class I HDAC activity and expression are associated with RelA/p65 activation in pancreatic cancer in vitro and in vivo. BMC Cancer 2009, 9:395.
27. Fritsche P., Seidler B., Schüler S., Schnieke A., Göttlicher M., Schmid R.M., Saur D., Schneider G. HDAC2 mediates therapeutic resistance of pancreatic cancer cells via the BH3-only protein NOXA. Gut 2009, 58:1399-1409.
28. Nakagawa M., Oda Y., Eguchi T., Aishima S.-I., Yao T., Hosoi F., Basaki Y., Ono M., Kuwano M., Tanaka M. Expression profile of class I histone deacetylases in human cancer tissues. Oncol. Rep. 2007, 18:769-774.
29. Miyake K., Yoshizumi T., Imura S., Sugimoto K., Batmunkh E., Kanemura H., Morine Y., Shimada M. Expression of hypoxia-inducible factor-1 [alpha], histone deacetylase 1, and metastasis-associated protein 1 in pancreatic carcinoma: correlation with poor prognosis with possible regulation. Pancreas 2008, 36:e1-e9.
30. Wang W., Gao J., Man X.-H., Li Z.-S., Gong Y.-F. Significance of DNA methyltransferase-1 and histone deacetylase-1 in pancreatic cancer. Oncol. Rep. 2009, 21:1439-1447.
31. Ouaissi M., Sielezneff I., Sastre B., Dahan L., Pirrò N. High histone deacetylase 7 (HDAC7) expression is significantly associated with adenocarcinomas of the pancreas. Ann. Surg. Oncol. 2008, 15:2318-2328.
32. Stenzinger A., Endris V., Klauschen F., Sinn B., Lorenz K., Warth A., Goeppert B., Ehemann V., Muckenhuber A., Kamphues C. High SIRT1 expression is a negative prognosticator in pancreatic ductal adenocarcinoma. BMC Cancer 2013, 13:450.
33. Tang J., Yan H., Zhuang S. Histone deacetylases as targets for treatment of multiple diseases. Clin. Sci. 2013, 124:651-662.
34. Abujamra A.L., dos Santos M.P., Roesler R., Schwartsmann G., Brunetto A.L. Histone deacetylase inhibitors: a new perspective for the treatment of leukemia. Leukemia Res. 2010, 34:687-695.
35. Bolden J.E., Peart M.J., Johnstone R.W. Anticancer activities of histone deacetylase inhibitors. Nat. Rev. Drug Discovery 2006, 5:769-784.
36. Carew J.S., Giles F.J., Nawrocki S.T. Histone deacetylase inhibitors: mechanisms of cell death and promise in combination cancer therapy[J]. Cancer Lett. 2008, 269:7-17.
37. Khan O., La Thangue N.B. HDAC inhibitors in cancer biology: emerging mechanisms and clinical applications. Immunol. Cell Biol. 2011, 90:85-94.
38. Duvic M., Talpur R., Ni X., Zhang C., Hazarika P., Kelly C., Chiao J.H., Reilly J.F., Ricker J.L., Richon V.M. Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL). Blood 2007, 109:31-39.
39. Koutsounas I., Giaginis C., Patsouris E., Theocharis S. Current evidence for histone deacetylase inhibitors in pancreatic cancer. World J. Gastroenterol.: WJG 2013, 19:813.
40. Schneider G., Krämer O.H., Fritsche P., et al. Targeting histone deacetylases in pancreatic ductal adenocarcinoma[J]. Journal of cellular and molecular medicine 2010, 14(6a):1255-1263.
41. Koutsounas I., Giaginis C., Theocharis S. Histone deacetylase inhibitors and pancreatic cancer: are there any promising clinical trials?. World J. Gastroenterol.: WJG 2013, 19:1173.
42. 1. Int. J. Biochem. Cell Biol. 2007, 39:1367-1374.
43. Chien W., Lee D.H., Zheng Y., Wuensche P., Alvarez R., Wen D.L., Aribi A.M., Thean S.M., Doan N.B., Said J.W. Growth inhibition of pancreatic cancer cells by histone deacetylase inhibitor belinostat through suppression of multiple pathways including HIF, NFkB, and mTOR signaling in vitro and in vivo. Mol. Carcinogen. 2013.
44. Sung V., Richard N., Brady H., Maier A., Kelter G., Heise C. Histone deacetylase inhibitor MGCD0103 synergizes with gemcitabine in human pancreatic cells. Cancer Sci. 2011, 102:1201-1207.
45. Qiao Z., Ren S., Li W., Wang X., He M., Guo Y., Sun L., He Y., Ge Y., Yu Q. Chidamide, a novel histone deacetylase inhibitor, synergistically enhances gemcitabine cytotoxicity in pancreatic cancer cells. Biochem. Biophys. Res. Commun. 2013.
46. Moore P.S., Barbi S., Donadelli M., Costanzo C., Bassi C., Palmieri M., Scarpa A. Gene expression profiling after treatment with the histone deacetylase inhibitor trichostatin A reveals altered expression of both pro-and anti-apoptotic genes in pancreatic adenocarcinoma cells. Biochim. Biophys. Acta (BBA) - Mol. Cell Res. 2004, 1693:167-176.
47. 2-M cell cycle arrest and apoptosis in pancreatic cancer cell lines. Cancer Lett. 2006, 237:143-154.
48. Wang G., He J., Zhao J., Yun W., Xie C., Taub J.W., Azmi A., Mohammad R.M., Dong Y., Kong W. Class I and class II histone deacetylases are potential therapeutic targets for treating pancreatic cancer. PLoS ONE 2012, 7:e52095.
49. Arlt A., Müerköster S.S., Schäfer H. Targeting apoptosis pathways in pancreatic cancer. Cancer Lett. 2013, 332:346-358.
50. Kauh J., Fan S., Xia M., Yue P., Yang L., Khuri F.R., Sun S.-Y. C-FLIP degradation mediates sensitization of pancreatic cancer cells to TRAIL-induced apoptosis by the histone deacetylase inhibitor LBH589. PLoS ONE 2010, 5:e10376.
51. Schüler S., Fritsche P., Diersch S., Arlt A., Schmid R.M., Saur D., Schneider G. Research HDAC2 attenuates TRAIL-induced apoptosis of pancreatic cancer cells. Mol. Cancer 2010, 9:80.
52. Natoni F., Diolordi L., Santoni C., Gilardini Montani M.S. Sodium butyrate sensitises human pancreatic cancer cells to both the intrinsic and the extrinsic apoptotic pathways. Biochim. Biophys. Acta (BBA) - Mol. Cell Res. 2005, 1745:318-329.
53. Marks P., Xu W.S. Histone deacetylase inhibitors: potential in cancer therapy. J. Cell Biochem. 2009, 107:600-608.
54. Dell'Aversana C., Lepore I., Altucci L. HDAC modulation and cell death in the clinic. Exp. Cell Res. 2012, 318:1229-1244.
55. Newbold A., Lindemann R.K., Cluse L.A., Whitecross K.F., Dear A.E., Johnstone R.W. Characterisation of the novel apoptotic and therapeutic activities of the histone deacetylase inhibitor romidepsin. Mol. Cancer Ther. 2008, 7:1066-1079.
56. Wiegmans A.P., Alsop A.E., Bots M., Cluse L.A., Williams S.P., Banks K.-M., Ralli R., Scott C.L., Frenzel A., Villunger A. Deciphering the molecular events necessary for synergistic tumor cell apoptosis mediated by the histone deacetylase inhibitor vorinostat and the BH3 mimetic ABT-737. Cancer Res. 2011, 71:3603-3615.
57. Donadelli M., Costanzo C., Beghelli S., Scupoli M.T., Dandrea M., Bonora A., Piacentini P., Budillon A., Caraglia M., Scarpa A. Synergistic inhibition of pancreatic adenocarcinoma cell growth by trichostatin A and gemcitabine. Biochim. Biophys. Acta (BBA) - Mol. Res. 2007, 1773:1095-1106.
58. Mitsiades N., Mitsiades C.S., Richardson P.G., McMullan C., Poulaki V., Fanourakis G., Schlossman R., Chauhan D., Munshi N.C., Hideshima T. Molecular sequelae of histone deacetylase inhibition in human malignant B cells. Blood 2003, 101:4055-4062.
59. García-Morales P., Gómez-Martínez A., Carrato A., Martínez-Lacaci I., Barberá V.M., Soto J.L., Carrasco-García E., Menéndez-Gutierrez M.P., Castro-Galache M.D., Ferragut J.A. Histone deacetylase inhibitors induced caspase-independent apoptosis in human pancreatic adenocarcinoma cell lines. Mol. Cancer Ther. 2005, 4:1222-1230.
60. P.A. Marks, Thioredoxin in cancer-role of histone deacetylase inhibitors, in: Seminars in Cancer Biology, Elsevier, 2006, pp. 436-443.
61. Ungerstedt J., Du Y., Zhang H., Nair D., Holmgren A. In vivo redox state of Human thioredoxin and redox shift by the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA). Free Radical Biol. Med. 2012.
62. Ungerstedt J., Sowa Y., Xu W.-S., Shao Y., Dokmanovic M., Perez G., Ngo L., Holmgren A., Jiang X., Marks P. Role of thioredoxin in the response of normal and transformed cells to histone deacetylase inhibitors. Proc. Nat. Acad. Sci. USA 2005, 102:673-678.
63. Wang B., Wang X.-b., Chen L.-y., Huang L., Dong R.-Z. Belinostat-induced apoptosis and growth inhibition in pancreatic cancer cells involve activation of TAK1-AMPK signaling axis. Biochem. Biophys. Res. Commun. 2013.
64. Ellis L., Hammers H., Pili R. Targeting tumor angiogenesis with histone deacetylase inhibitors. Cancer Lett. 2009, 280:145-153.
65. Hideshima T. Histone Deacetylase Inhibitors in Multiple Myeloma. Myeloma Therapy 2009, Springer, pp. 379-392.
66. Chen L., Endler A., Shibasaki F. Hypoxia and angiogenesis: regulation of hypoxia-inducible factors via novel binding factors. Exp. Mol. Med. 2009, 41:849-857.
67. Ellis L., Pili R. Histone deacetylase inhibitors: advancing therapeutic strategies in hematological and solid malignancies. Pharmaceuticals 2010, 3:2441-2469.
68. Wang S., Li X., Parra M., Verdin E., Bassel-Duby R., Olson E.N. Control of endothelial cell proliferation and migration by VEGF signaling to histone deacetylase 7. Proc. Nat. Acad. Sci. 2008, 105:7738-7743.
69. Liu T., Kuljaca S., Tee A., Marshall G.M. Histone deacetylase inhibitors: multifunctional anticancer agents. Cancer Treat. Rev. 2006, 32:157-165.
70. Qian D.Z., Kato Y., Shabbeer S., Wei Y., Verheul H.M., Salumbides B., Sanni T., Atadja P., Pili R. Targeting tumor angiogenesis with histone deacetylase inhibitors: the hydroxamic acid derivative LBH589. Clin. Cancer Res. 2006, 12:634-642.
71. Maier H.J., Wirth T., Beug H. Epithelial-mesenchymal transition in pancreatic carcinoma. Cancers (Basel) 2010, 2:2058-2083.
72. Aghdassi A., Sendler M., Guenther A., Mayerle J., Behn C.-O., Heidecke C.-D., Friess H., Büchler M., Evert M., Lerch M.M. Recruitment of histone deacetylases HDAC1 and HDAC2 by the transcriptional repressor ZEB1 downregulates E-cadherin expression in pancreatic cancer. Gut 2012, 61:439-448.
73. Kumagai T., Wakimoto N., Yin D., Gery S., Kawamata N., Takai N., Komatsu N., Chumakov A., Imai Y., Koeffler H.P. Histone deacetylase inhibitor, suberoylanilide hydroxamic acid (Vorinostat, SAHA) profoundly inhibits the growth of human pancreatic cancer cells. Int. J. Cancer 2007, 121:656-665.
74. Iwatsuki M., Mimori K., Yokobori T., Ishi H., Beppu T., Nakamori S., Baba H., Mori M. Epithelial-mesenchymal transition in cancer development and its clinical significance. Cancer Sci. 2010, 101:293-299.
75. Arumugam T., Ramachandran V., Fournier K.F., Wang H., Marquis L., Abbruzzese J.L., Gallick G.E., Logsdon C.D., McConkey D.J., Choi W. Epithelial to mesenchymal transition contributes to drug resistance in pancreatic cancer. Cancer Res. 2009, 69:5820-5828.
76. von Burstin J., Eser S., Paul M.C., Seidler B., Brandl M., Messer M., von Werder A., Schmidt A., Mages J., Pagel P. E-cadherin regulates metastasis of pancreatic cancer in vivo and is suppressed by a SNAIL/HDAC1/HDAC2 repressor complex. Gastroenterology 2009, 137:361-371. e365.
77. Jeon H.W., Lee Y.M. Inhibition of histone deacetylase attenuates hypoxia-induced migration and invasion of cancer cells via the restoration of RECK expression. Mol. Cancer Ther. 2010, 9:1361-1370.
78. Liu L.-T., Chang H.-C., Chiang L.-C., Hung W.-C. Histone deacetylase inhibitor up-regulates RECK to inhibit MMP-2 activation and cancer cell invasion. Cancer Res. 2003, 63:3069-3072.
79. Thurn K.T., Thomas S., Moore A., Munster P.N. Rational therapeutic combinations with histone deacetylase inhibitors for the treatment of cancer. Future Oncol. 2011, 7:263-283.
80. Iwahashi S., Ishibashi H., Utsunomiya T., Morine Y., Ochir T.L., Hanaoka J., Mori H., Ikemoto T., Imura S., Shimada M. Effect of histone deacetylase inhibitor in combination with 5-fluorouracil on pancreas cancer and cholangiocarcinoma cell lines. J. Med. Invest.: JMI 2011, 58:106-109.
81. Richards D., Boehm K., Waterhouse D., Wagener D., Krishnamurthi S., Rosemurgy A., Grove W., Macdonald K., Gulyas S., Clark M. Gemcitabine plus CI-994 offers no advantage over gemcitabine alone in the treatment of patients with advanced pancreatic cancer: results of a phase II randomized, double-blind, placebo-controlled, multicenter study. Ann. Oncol. 2006, 17:1096-1102.
82. Millward M., Price T., Townsend A., Sweeney C., Spencer A., Sukumaran S., Longenecker A., Lee L., Lay A., Sharma G. Phase 1 clinical trial of the novel proteasome inhibitor marizomib with the histone deacetylase inhibitor vorinostat in patients with melanoma, pancreatic and lung cancer based on in vitro assessments of the combination. Invest. New Drug 2012, 30:2303-2317.
83. Doss H., Jones S., Infante J., Spigel D., Willcutt N., Lamar R., Barton J., Keegan M., Burris H. A phase I trial of romidepsin in combination with gemcitabine in patients with pancreatic and other advanced solid tumors. J. Clin. Oncol. 2008, 26:25-67.
84. Wang H., Cao Q., Dudek A.Z. Phase II study of panobinostat and bortezomib in patients with pancreatic cancer progressing on gemcitabine-based therapy. Anticancer Res. 2012, 32:1027-1031.
85. Chan E., Arlinghaus L.R., Cardin D.B., Goff L.W., Yankeelov T.E., Berlin J., McClanahan P., Holloway M., Parikh A.A., Abramson R.G. Phase I trial of chemoradiation with capecitabine and vorinostat in pancreatic cancer. J. Clin. Oncol. (Meeting Abstracts) 2013, 225.
86. de Bono J.S., Kristeleit R., Tolcher A., Fong P., Pacey S., Karavasilis V., Mita M., Shaw H., Workman P., Kaye S. Phase I pharmacokinetic and pharmacodynamic study of LAQ824, a hydroxamate histone deacetylase inhibitor with a heat shock protein-90 inhibitory profile, in patients with advanced solid tumors. Clin. Cancer Res. 2008, 14:6663-6673.
87. Undevia S., Kindler H., Janisch L., Olson S., Schilsky R., Vogelzang N., Kimmel K., Macek T., Ratain M. A phase I study of the oral combination of CI-994, a putative histone deacetylase inhibitor, and capecitabine. Ann. Oncol. 2004, 15:1705-1711.
88. Di Costanzo F., Carlini P., Doni L., Massidda B., Mattioli R., Iop A., Barletta E., Moscetti L., Recchia F., Tralongo P. Gemcitabine with or without continuous infusion 5-FU in advanced pancreatic cancer: a randomised phase II trial of the Italian oncology group for clinical research (GOIRC). Brit. J. Cancer 2005, 93:185-189.
89. Kulke M.H., Tempero M.A., Niedzwiecki D., Hollis D.R., Kindler H.L., Cusnir M., Enzinger P.C., Gorsch S.M., Goldberg R.M., Mayer R.J. Randomized phase II study of gemcitabine administered at a fixed dose rate or in combination with cisplatin, docetaxel, or irinotecan in patients with metastatic pancreatic cancer: CALGB 89904. J. Clin. Oncol. 2009, 27:5506-5512.
90. Colucci G., Labianca R., Di Costanzo F., Gebbia V., Cartenì G., Massidda B., Dapretto E., Manzione L., Piazza E., Sannicolò M. Randomized phase III trial of gemcitabine plus cisplatin compared with single-agent gemcitabine as first-line treatment of patients with advanced pancreatic cancer: the GIP-1 study. J. Clin. Oncol. 2010, 28:1645-1651.
91. Dovzhanskiy D.I., Arnold S.M., Hackert T., Oehme I., Witt O., Felix K., Giese N., Werner J. Experimental in vivo and in vitro treatment with a new histone deacetylase inhibitor belinostat inhibits the growth of pancreatic cancer. BMC Cancer 2012, 12:226.
92. Nitiss J.L. Targeting DNA topoisomerase II in cancer chemotherapy. Nat. Rev. Cancer 2009, 9:338-350.
93. Piacentini P., Donadelli M., Costanzo C., Moore P.S., Palmieri M., Scarpa A. Trichostatin A enhances the response of chemotherapeutic agents in inhibiting pancreatic cancer cell proliferation. Virchows Arch. 2006, 448:797-804.
94. Spratlin J., Pitts T., Kulikowski G., Morelli M., Tentler J., Serkova N., Eckhardt S. Synergistic activity of histone deacetylase and proteasome inhibition against pancreatic and hepatocellular cancer cell lines. Anticancer Res. 2011, 31:1093-1103.
95. Bai J., Demirjian A., Sui J., Marasco W., Callery M.P. Histone deacetylase inhibitor trichostatin A and proteasome inhibitor PS-341 synergistically induce apoptosis in pancreatic cancer cells. Biochem. Biophys. Res. Commun. 2006, 348:1245-1253.
96. Nawrocki S.T., Carew J.S., Pino M.S., Highshaw R.A., Andtbacka R.H., Dunner K., Pal A., Bornmann W.G., Chiao P.J., Huang P. Aggresome disruption: a novel strategy to enhance bortezomib-induced apoptosis in pancreatic cancer cells. Cancer Res. 2006, 66:3773-3781.
97. Bots M., Johnstone R.W. Rational combinations using HDAC inhibitors. Clin. Cancer Res. 2009, 15:3970-3977.
98. Wright J.J. Combination therapy of bortezomib with novel targeted agents: an emerging treatment strategy. Clin. Cancer Res. 2010, 16:4094-4104.
99. Hwang R.F., Moore T., Arumugam T., Ramachandran V., Amos K.D., Rivera A., Ji B., Evans D.B., Logsdon C.D. Cancer-associated stromal fibroblasts promote pancreatic tumor progression. Cancer Res. 2008, 68:918-926.
100. Olive K.P., Jacobetz M.A., Davidson C.J., Gopinathan A., McIntyre D., Honess D., Madhu B., Goldgraben M.A., Caldwell M.E., Allard D. Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer. Science 2009, 324:1457-1461.
101. Chun S.G., Zhou W., Yee N.S. Combined targeting of histone deacetylases and hedgehog signaling enhances cytoxicity in pancreatic cancer. Cancer Biol. Ther. 2009, 8:1328-1339.
102. Zhao G., Cui J., Zhang J., Qin Q., Chen Q., Yin T., Deng S., Liu Y., Liu L., Wang B. SIRT1 RNAi knockdown induces apoptosis and senescence, inhibits invasion and enhances chemosensitivity in pancreatic cancer cells. Gene Ther. 2011, 18:920-928.
103. Stimson L., La Thangue N.B. Biomarkers for predicting clinical responses to HDAC inhibitors. Cancer Lett. 2009, 280:177-183.
104. Khan O., Fotheringham S., Wood V., Stimson L., Zhang C., Pezzella F., Duvic M., Kerr D.J., La Thangue N.B. HR23B is a biomarker for tumor sensitivity to HDAC inhibitor-based therapy. Proc. Nat. Acad. Sci. 2010, 107:6532-6537.
105. Weichert W. HDAC expression and clinical prognosis in human malignancies. Cancer Lett. 2009, 280:168-176.
106. Garcia-Manero G., Yang H., Bueso-Ramos C., Ferrajoli A., Cortes J., Wierda W.G., Faderl S., Koller C., Morris G., Rosner G. Phase 1 study of the histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid [SAHA]) in patients with advanced leukemias and myelodysplastic syndromes. Blood 2008, 111:1060-1066.
107. Miller C.P., Singh M.M., Valle R.-D., Manton C.A., Chandra J. Therapeutic strategies to enhance the anticancer efficacy of histone deacetylase inhibitors. J. Biomed. Biotechnol. 2011, 2011.
108. Iglesias-Linares A., Yañez-Vico R.M., González-Moles M.A. Potential role of HDAC inhibitors in cancer therapy: Insights into oral squamous cell carcinoma. J. Oral oncology 2010, 46(5):323-329.
109. Carew J.S., Giles F.J., Nawrocki S.T. Histone deacetylase inhibitors: mechanisms of cell death and promise in combination cancer therapy. J. Cancer letters 2008, 269(1):7-17.
110. Frew A.J., Johnstone R.W., Bolden J.E. Enhancing the apoptotic and therapeutic effects of HDAC inhibitors. J. Cancer letters 2009, 280(2):125-133.